Research progress on T-cell engager drugs
10.13200/j.cnki.cjb.004514
- VernacularTitle:T细胞衔接器药物的研究进展
- Author:
Dongfeng CHANG
1
Author Information
1. CSPC Megalith Biopharmaceutical Co., Ltd., Shijiazhuang 050015, Hebei Province, China
- Publication Type:Journal Article
- Keywords:
T-cell engager(TCE);
Bispecific targeting mechanism;
Solid tumors;
Autoimmune diseases
- From:
Chinese Journal of Biologicals
2026;39(03):350-359
- CountryChina
- Language:Chinese
-
Abstract:
T-cell engager(TCE) bridges T cells to target cells via dual-targeting, activating specific cytotoxicity of T cells,revolutioni-zing oncology and autoimmune therapies. In the field of hematological tumor treatment, TCE drug CD19/CD3 bispecific antibody Blinatumomab improves outcomes in relapsed/refractory B-cell malignancies. For solid tumors, cha llenges include antigen off-target toxicity and immunosuppressive microenvironments(such as insufficient T-cell infiltration and enrichment of inhibitory factors). Strategies prioritize high-specificity targets [such as delta-like protein 3(DLL3) and claudin 18.2(CLDN18.2)], exemplified by Tarlatamab that has been approved for small cell lung cancer. In the field of autoimmune disease treatment, TCE can accurately deplete pathological cell subsets [such as CD3/CD19 for B/pre-plasma cells,CD3/B-cell maturation antigen(BCMA)for plasma cells], breaking through the limitations of traditional therapies. In this paper, the mechanism of TCE drugs, the role of CD3 as a signal hub in TCE targeted therapy and the research progress on TCE drugs are reviewed in order to provide references for optimizing the clinical transformation pathway of TCE and developing a new generation of immune reprogramming technology.
